Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Non-randomized Pivotal Clinical Study to Assess the Safety and Performance of the Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299 is registered in ClinicalTrials.gov with Xeltis as lead sponsor.

NCT NCT05473299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05473299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Non-randomized Pivotal Clinical Study to Assess the Safety and Performance of the Xeltis Hemodialysis Access Graft: aXess Pivotal Study
Lead sponsor
Xeltis
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 4, 2022
Completion date
December 31, 2029
Enrollment
120 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease